Elke Langkopf
Overview
Explore the profile of Elke Langkopf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eckhardt M, Hauel N, Himmelsbach F, Langkopf E, Nar H, Mark M, et al.
Bioorg Med Chem Lett
. 2008 May;
18(11):3158-62.
PMID: 18485703
Systematic variations of the xanthine scaffold in close analogs of development compound BI 1356 led to the class of 3,5-dihydro-imidazo[4,5-d]pyridazin-4-ones which provided, after substituent screening, a series of highly potent...
2.
Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M
J Pharmacol Exp Ther
. 2008 Jan;
325(1):175-82.
PMID: 18223196
BI 1356 [proposed trade name ONDERO; (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] is a novel dipeptidyl peptidase (DPP)-4 inhibitor under clinical development for the treatment of type 2 diabetes. In this study, we investigated the...
3.
Pautsch A, Stadler N, Wissdorf O, Langkopf E, Moreth W, Streicher R
J Biol Chem
. 2008 Jan;
283(14):8913-8.
PMID: 18198182
Disrupting the interaction between glycogen phosphorylase and the glycogen targeting subunit (G(L)) of protein phosphatase 1 is emerging as a novel target for the treatment of type 2 diabetes. To...
4.
Eckhardt M, Langkopf E, Mark M, Tadayyon M, Thomas L, Nar H, et al.
J Med Chem
. 2007 Dec;
50(26):6450-3.
PMID: 18052023
A new chemical class of potent DPP-4 inhibitors structurally derived from the xanthine scaffold for the treatment of type 2 diabetes has been discovered and evaluated. Systematic structural variations have...
5.
Solca F, Baum A, Langkopf E, Dahmann G, Heider K, Himmelsbach F, et al.
J Pharmacol Exp Ther
. 2004 Jun;
311(2):502-9.
PMID: 15199094
Overexpression of the epidermal growth factor receptors (EGFRs) and human epidermal growth factor receptor 2 occurs frequently in human cancers and is associated with aggressive tumor behavior and poor patient...
6.
Eger A, Stockinger A, Park J, Langkopf E, Mikula M, Gotzmann J, et al.
Oncogene
. 2004 Feb;
23(15):2672-2680.
PMID: 14755243
Several signalling pathways contribute to the regulation of epithelial to mesenchymal transition (EMT), either during developmentally regulated processes or in cancer progression and metastasis. Induction of EMT in fully polarized...